This study is designed to test a new medicine called **MTX-463** for people with a lung disease called Idiopathic Pulmonary Fibrosis (**IPF**). IPF makes it hard to breathe because it causes lung tissue to become thick and stiff. In this study, participants will receive either MTX-463 or a placebo (a substance with no active medicine) through an intravenous (IV) infusion, which is when medicine is given directly into a vein.

To be eligible, participants must be at least 40 years old, have a recent IPF diagnosis, and meet other health criteria. The study lasts for 28 weeks, with treatments every 4 weeks. Participants can stay on their current IPF medications, either pirfenidone or nintedanib, during the study.

• Participants will receive IV infusions every 4 weeks from Day 0 to Week 20.
• The study includes a total of 7 visits over 28 weeks for monitoring and assessments.
• Participants will have their lung function and blood checked regularly for safety.

If you have IPF and meet the criteria, this study may offer a chance to try a new treatment while helping researchers learn more about MTX-463.